Chronic myelogenous leukaemia (CML), the prototype chronic myeloproliferative neoplasm (CMPN) is one of the leukaemias which can be easily diagnosed in view of typical haematological and morphological findings, in an appropriate clinical setting. CML is diagnosed in the presence of features such as splenomegaly, leucocytosis with myelocyte and neutrophil predominance, low neutrophil alkaline phosphatase (NAP) score, hypercellular bone marrow (BM) with granulocytic or granulocytic/megakaryocytic hyperplasia. Patients lacking typical features of specific CMPN, need to be differentiated from other primary haematological and secondary disorders showing myeloproliferation[@ref1]--[@ref3].

The *sine qua non* of CML, t(9;22)(q34;q11) and/or *BCR-ABL* positivity must be detected in all cases of CML in chronic phase (CP) and accelerated phase (AP)/blast crisis (BC)[@ref1]. t(9;22) or Philadelphia (Ph) chromosome is detected in 90-95 per cent patients on cytogenetic analysis. A few CML patients may not demonstrate Ph chromosome (Ph chromosome negative and *BCR-ABL* positive), yet have clinical course and morphological features just like typical CML[@ref1]--[@ref3]. Additional cytogenetic abnormalities are associated with disease progression from CML-CP towards CML-AP/BC in nearly 70-80 per cent patients[@ref2][@ref3].

Ph chromosome/t(9;22) is a diagnostic hallmark of CML, however it is detected in other haematological malignant disorders as well \[10-20% adult acute lymphoblastic leukaemia (ALL), 2-5 per cent paediatric ALL, \<5 per cent cases of acute myeloblastic leukaemia (AML), and rarely in multiple myeloma, lymphoma and chronic neutrophilic leukaemia (CNL) patients\][@ref2].

Presence of molecular counterpart of Ph chromosome/t(9;22) in CML patients (Ph positive and Ph negative) is confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) or fluorescence *in situ* hybridization (FISH). In addition, molecular analysis contributes to identify various molecular subtypes of CML-like disorders and makes differential diagnoses on the basis of 3 breakpoint cluster (*bcr*) regions involved in the translocation between *BCR* and *ABL* genes. Disease phenotype of patients varies with different breakpoints involved, resulting in varying sizes of fusion mRNA transcripts and chimeric proteins[@ref1].

Major bcr (M-bcr) is almost always involved in CML patients, resulting in b2a2 and b3a2 mRNA transcripts, p210 chimeric protein, and classical CML phenotype. Minor bcr (m-bcr), e1a2 mRNA transcripts and p190 chimeric protein, are most frequently associated with Ph positive ALL. However small amount of e1a2 mRNA transcripts, due to alternate splicing, can also be detected in many patients with classical CML phenotype. m-bcr involvement may also be seen in rare CML patients with monocytosis, thus resembling chronic myelomonocytic leukaemia (CMML). CML patients with breakpoint in micro bcr (μ-bcr), e19a2 and p230 chimeric protein, may demonstrate prominent neutrophilic and/or thrombocytosis; these should not be diagnosed as chronic neutrophilic leukaemia (CNL) or essential thrombocythaemia (ET)[@ref1]. Therefore, in the current scenario cytogenetic and molecular analyses of CML patients have become mandatory in order to undertake diagnostic evaluation and monitor/predict response to newer molecular targeted treatment modalities like imatinib mesylate (IM)[@ref1]--[@ref5]. Variable frequencies of *BCR-ABL* fusion transcripts have been reported from different parts of the world[@ref2][@ref6]--[@ref11]; a few documented b2a2 to be more common[@ref7][@ref8], whereas other studies found b3a2 to be more common[@ref9]--[@ref11]. Co-expression of *BCR-ABL* fusion transcripts, though rare, presents an interesting scenario for future exploration.

Despite being the commonest leukaemia in Asia[@ref12], there are very few studies published from India, documenting the frequency of *BCR-ABL* fusion transcripts[@ref13]--[@ref15]. A very wide range of Ph positivity (67-95%) has been reported in various studies on CML patients from India, without having the benefit of gold standard molecular analysis[@ref16]--[@ref22]. However, Ph chromosome positivity/negativity (and other cytogenetic abnormalities) in relation to *BCR-ABL* fusion transcripts has not been analyzed earlier among Indian patients.

Very few patients can afford to purchase IM on their own in India. Approximately 95 per cent CML patients are provided IM as a first-line treatment, through the Glivec International Patient Assistance Program (GIPAP)[@ref23]. Several CML patients are prescribed some form of treatment, without optimal diagnostic work up. This may alter their haematological and/or cytogenetic profiles though molecular analysis always remains informative[@ref23].

We present here our experience of analysis of a large number of CML patients being diagnosed and treated at Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh. This study was planned to document in a large group of CML patients various types of *BCR-ABL* fusion transcripts in different phases of CML (single or co-expression of more than one type of fusion transcript) and to compare the Ph chromosome positivity/negativity *vis-a-vis BCR-ABL* fusion transcripts.

Material & Methods {#sec1-1}
==================

Consecutively diagnosed CML patients in chronic phase, accelerated phase and blast crisis were recruited in this study, during June 2004 to February 2009. These patients were managed in the OPD and wards, under the adult haematology services of Internal Medicine department of PGIMER, Chandigarh. Diagnosis of different phases of CML was made according to the WHO criteria[@ref1]. This study protocol was approved by the institutional ethics committee. Informed consent was obtained from all the subjects.

*Blood counts, morphology and lineage assignment*: Following parameters along with careful morphological appraisal, were routinely evaluated in all the patients: complete blood counts (CBC), differential leucocyte count (DLC), NAP score, BM aspirate smears, BM biopsy imprint smears, BM biopsy sections \[hematoxylin & eosin (H & E) stain, reticulin stain\]. Special attention was paid to blasts, eosinophils, and basophils. Normal range of NAP score in our laboratory is 36-140. Cytochemistry \[myeloperoxidase (MPO), Periodic acid Schiff (PAS) and sudan black B stains\], immunocytochemistry and/or flowcytometry techniques were employed for characterization of blast cells in CML-BC patients, wherever indicated.

*Cytogenetic analysis*: Bone marrow samples, with and without peripheral blood leucocyte cultures (PBLC) were processed and analyzed to identify acquired cytogenetic abnormalities (Ph chromosome and others) in all CML patients, as baseline diagnostic work up. Ph chromosome positivity was expressed as percentage of Ph positive metaphases out of all metaphases analyzed. A minimum of 20 metaphases were analyzed routinely according to ISCN guidelines[@ref24].

*Qualitative multiplex RT-PCR*: Multiplex RT-PCR for *BCR/ABL* hybrid transcripts was performed according to the previously described methods[@ref25][@ref26]. Total cellular RNA from peripheral blood mononuclear cells (PBMC) was extracted by Qiagen kits (QIAamp blood mini kit, Germany). RNA was reverse transcribed to make complimentary DNA (cDNA) copies using a commercially available kit (Revert Aid First strand cDNA synthesis kit, MBI Fermentas, European Union). Integrity of cDNA was checked by amplifying β-actin gene. PCR primers specific to the DNA sequences of portions of *BCR/ABL* were used to amplify the cDNA. The PCR products were separated by agarose gel electrophoresis and visualized by UV transillumination.

The sequences of oligonucleotide primers (Sigma-Aldrich Chemicals Pvt. Ltd., Bangalore, India) used in multiplex RT-PCR for *BCR-ABL* fusion transcripts as the target gene are as follows:
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Co-expression of b3a2 and e19a2, and b2a2 and e19a2 has not been validated by sequencing. Non-parametric Kruskal-Wallis and Mann-Whitney tests were used for statistical analysis.

Results {#sec1-2}
=======

All 208 CML patients included in this study were positive for *BCR-ABL* transcripts. CML-CP was diagnosed in 183, CML-AP in 6 and CML-BC in 19 patients ([Table I](#T1){ref-type="table"}). Among 208 CML patients, b3a2 transcripts were most commonly detected (139, 66.82%) followed by b2a2 (60, 28.84%), b3a2 + b2a2 (7, 3.36%), b3a2 + e19a2 and b2a2 + e19a2 (1 each, 0.48%).

###### 

Results of cytogenetic & molecular analysis in CML patients (n=208)
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Among 183 CML-CP patients, b3a2 transcripts were most commonly detected (123, 67.21%) followed by b2a2 (52, 28.42%), b3a2 + b2a2 (7, 3.83%) and b3a2 + e19a2 (1, 0.55%). The frequency of b3a2 and b2a2 types of hybrid transcripts was significantly different, among the whole group of 208 patients as well as in CML-CP patients (*P*\<0.0001). The frequency of b3a2 and b2a2 types of hybrid transcripts was not significantly different, among the 6 CML-AP patients as well as in 19 CML-BC patients. Co-expressed hybrid transcripts were detected in 8 of 183 (4.38%) CML-CP patients (b3a2 + b2a2 in 7 and b3a2 + e19a2 in 1) and in 1 of 19 (5.26%) CML-BC patient (b2a2 + e19a2) ([Table I](#T1){ref-type="table"}).

At the cytogenetic level, 200 (96.15%) patients were positive (Ph positive & *BCR-ABL* positive CML) and 8 negative for Ph chromosome (Ph negative & *BCR-ABL* positive CML). All of these Ph negative *BCR-ABL* positive patients were in CML-CP. Four of the 123 (3.25%) had b3a2 transcripts (UPN 23, 139, 151 and 188) and 4 of 52 (7.69%) had b2a2 transcripts (UPN 23, 64, 162 and 199); the difference in the frequencies was not significant.

Additional cytogenetic abnormalities were detected in 3.8 per cent CP patients and 44 per cent in AP/BC patients. Double Ph chromosome was observed in 4 CP, 2 AP and 3 BC patients; +8 in 4 CP, 1 AP and 2 BC patients; +19 in 2 BC patients. b3a2 and b2a2 types of hybrid transcripts did not show significantly different predilection for additional cytogenetic findings. Rarely encountered co-expressed transcripts b3a2 + b2a2, b3a2 + e19a2 and b2a2 + e19a2 were not associated with additional cytogenetic abnormalities ([Table II](#T2){ref-type="table"}).

###### 

Additional cytogenetic findings and *BCR-ABL* transcripts in CML patients
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Median age of the total study group was 38 years (range 13-74 yr). Median age of CML patients with b2a2 transcripts was 42 in CP, 59 in AP and 35 years in BC; and for those with b3a2 transcripts was 37 in CP, 40 in AP and 31 years in BC. Although median age of CML patients with b2a2 transcripts was higher than those with b3a2 transcripts, the difference was not statistically significant.

Male:female ratio was 1.85:1 for CML-CP, 6:1 for CML-AP and 3.75:1 for CML-BC group, with relative over-representation of males in CML-AP and CML-BC groups. There was no significant difference in the sex distribution with respect to b3a2 or b2a2 transcripts in CML-CP and CML-BC patients.

Discussion {#sec1-3}
==========

Guidelines have been formulated by the WHO to facilitate the diagnosis of CML and various CMPNs/related disorders[@ref1]. However, a few CMPN cases possess overlapping features. Therefore, the entities which must be differentiated from CML are other CMPNs \[(essential thrombocythemia - ET, chronic idiopathic myelofibrosis - CIMF and polycythemia vera - PV); morphological variants (depending upon the predominant granulocyte cell type) *e.g*. chronic neutrophilic leukaemia (CNL) and chronic eosinophilic leukaemia (CEL)\] and myelodysplastic/myeloproliferative neoplasms (chronic myelomonocytic leukaemia - CMML, juvenile myelomonocytic leukaemia - JMML, atypical CML - aCML and unclassifiable myelodysplastic/myeloproliferative neoplasm). Leukemoid reaction always needs to be excluded[@ref1]--[@ref3].

Detection of various types of the transcripts in CML patients has been addressed in a few studies from different geographic locations[@ref6]--[@ref11] and from India[@ref13]--[@ref15]. Very few studies have detected co-expressed transcripts and included large number of CML patients ([Table III](#T3){ref-type="table"}). CML is the commonest leukaemia in adult patients in Asia[@ref12], however there are only few studies published encompassing the molecular analyses of adult CML patients in India[@ref13]--[@ref15]. Possibly due to cytogenetic analysis being a very time consuming and labour intensive technique, these studies have focused either on RT-PCR alone[@ref13] or RT-PCR and FISH techniques only[@ref14]. RT-PCR along with brief mention of cytogenetic analysis (only Ph positivity) has been reported in one study[@ref15].

###### 

Comparison of Indian studies on frequency of Ph positivity with and without molecular studies
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The frequency of b3a2 was reported as 55 per cent and b2a2 as 40 per cent in Caucasian population[@ref6]. Two other studies found higher frequency of b2a2 transcripts[@ref7][@ref8], whereas three reports document the comparison of frequencies of b3a2 and b2a2 transcripts among adult CML patients from western hemisphere[@ref9]--[@ref11]. Only one study has included more than 100 CML patients[@ref9]. Paz-y-Miño *et al*[@ref7] found frequencies of 5.4 per cent for the b3a2 transcripts and 94.6 per cent for the b2a2 transcripts in Ecuadorian Mestizos CML patients.

Rosas-Cabral *et al*[@ref8] detected b3a2 *BCR-ABL* transcripts in 28 per cent cases, b2a2 in 59 per cent cases, and 13 per cent with both b3a2/b2a2 transcripts among 97 Philadelphia-positive CML Mexican cases. Ruiz-Argüelles *et al*[@ref9] studied a group of 238 Mexican Mestizos patients with Ph positive CML; 54.2 per cent showed b3a2 subtype, 43.2 per cent b2a2 and 2.5 per cent b3a2/b2a2.

de Lemos *et al*[@ref10] from Brazil performed RT-PCR for *BCR-ABL* in 22 CML patients. Of these patients, 15 (68%) were in chronic phase, five (23%) in accelerated phase and two (9%) in blastic phase; 59 per cent patients had b3a2 and 41 per cent had b2a2 transcripts.

Yaghmaie *et al*[@ref11] studied 75 adult Iranian CML patients; 83 per cent patients expressed one of the p210 *BCR-ABL* transcripts (b3a2, 63% and b2a2, 20%), while the remaining showed one of the transcripts of b3a3, b2a3, e1a2 or co-expression of b3a2 and b2a2. b3a2 and b2a2 were co-expressed in 5 per cent patients.

Mondal *et al*[@ref13] studied 122 CML patients and details of cytogenetic analysis are not provided. Out of 122, 112 (91.8%) patients were positive for one or more of the four junctional types tested.

Polampalli *et al*[@ref14] studied 202 CML patients; 138 (68%) had the *b3a2* type *BCR-ABL* transcript and 64 (32%) had the *b2a2* type. On comparing the RT-PCR with FISH in 186 patients, t(9;22) was detected in 78.6 per cent patients. FISH technique also found additional/variant cytogenetic abnormalities in 26.88 per cent patients. Sharma *et al*[@ref15] studied 87 CML-CP patients: *b3a2 BCR-ABL* transcripts were detected in 54 per cent, *b2a2* transcripts in 38 per cent and *b3a2* + *b2a2* transcripts in 8 per cent patients. These authors mentioned 100 per cent Ph positive metaphases in the 'pre-treated' group of 57 patients ([Table IV](#T4){ref-type="table"}).

###### 

Comparison of frequency of *BCR-ABL* transcripts types in recent studies
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In our study b3a2 transcripts were most commonly detected (66.82%) among 208 CML patients, followed by b2a2 (28.84%). Similar was the case with 183 CML-CP patients; b3a2 transcripts were most commonly detected (67.21%) followed by b2a2 (28.42%). Co-expression of at least two types of hybrid transcripts was detected in 4.33 per cent patients: 7 CML-CP patients had b3a2 + b2a2 transcripts, 1 CML-CP patients had b3a2 + e19a2 transcripts, and 1 CML-BC patient had b2a2 + e19a2 transcripts. Latter two transcript types have not been detected in the earlier studies. Low expression of e1a2 (p190) transcripts may be found with classical b3a2/b2a2 (p210) transcripts in more than 90 per cent CML patients[@ref1], however, neither the aforementioned studies[@ref6]--[@ref11][@ref14][@ref15], nor we detected e1a2 (p190) transcripts. These could have been detected by our PCR protocol. Co-expression of b3a2 and e19a2, and b2a2 and e19a2 was not validated by sequencing. All the studies[@ref6]--[@ref11][@ref14][@ref15], except one[@ref13], have not performed sequencing for this purpose.

Association of b2a2 with younger age has been suggested by Mondal *et al*[@ref13] (without reaching statistical significance level). Median age of our CML patients with b2a2 transcripts was higher than those with b3a2 transcripts, though there was overlap in the range and the difference was not statistically significant. No sex predilection was found with regard to b3a2 versus b2a2 transcripts.

Cytogenetic study of CML patients was reported from our department in 1978[@ref16]. [Table III](#T3){ref-type="table"} shows studies published 1990s onwards, with Ph positivity being reported in 67-95 per cent Indian CML patients[@ref17]--[@ref22]. This leaves a lot of 'CML' patients whose diagnosis remains uncertain/questionable, according to the WHO criteria[@ref1]. Therefore, it is important to have the gold standard molecular testing (FISH or RT-PCR) for comparison to ascertain the true frequency of Ph positivity or negativity in CML patients.

Ph positivity in our patients was higher compared to many Indian studies[@ref14][@ref17][@ref19]--[@ref22]. Additional cytogenetic abnormalities frequently associated with disease evolution include +Ph, +8, +19 and i(17q)[@ref1]--[@ref3]. We document here that the additional cytogenetic abnormalities are not associated with any particular *BCR-ABL* transcript type.

Cytogenetic and molecular analysis has become mandatory in order to make a correct diagnosis and predict/monitor response to newer molecular targeted treatment modalities like imatinib mesylate. Cytogenetic study and qualitative RT-PCR have prime importance at the time of diagnosis, whereas serial quantitative RQ-PCR is recommended for therapeutic monitoring[@ref4][@ref5].

Diagnostic criteria of various disorders are evolving very rapidly and it is difficult to keep pace with the developments, especially in the developing countries. With the application of standard criteria, definite diagnosis of CML can be made most easily, as compared to other CMPDs[@ref1]. Therefore, it is imperative to document the features of the diseases as completely as possible, for analysis of various features at the time of diagnosis.
